Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Charles A Odonkor, MD
- Phone Number: 203-767-1555
- Email: charles.odonkor@yale.edu
Study Contact Backup
- Name: Muhammad U Siddique, MD
- Email: muhammad.siddique@yale.edu
Study Locations
-
-
Connecticut
-
Old Saybrook, Connecticut, United States, 06475
- Recruiting
- Yale New Haven Health Old Saybrook Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of chronic pain (generally pain duration of at least 3-6 months) localized to an anatomical region appropriate for cryoneurolysis as determined by the treating physician.
- Planned cryoneurolysis procedure as part of standard clinical care.
- Ability to provide written informed consent.
- Ability and willingness to complete baseline and follow-up questionnaires.
Exclusion Criteria:
- Cryoneurolysis performed as part of a separate investigational trial in which data sharing is not permitted.
- Active infection or other clinical contraindication to the procedure as determined by the treating clinician.
- Life expectancy of less than 12 months in the judgment of the treating clinician.
- Any condition that, in the investigator's opinion, would interfere with study participation or completion of follow-up, such as severe psychiatric instability or active substance use that precludes reliable follow-up
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Participants undergoing cryoneurolysis
Participants undergoing cryoneurolysis for chronic pain as part of standard clinical care.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of participants with improvement in pain
Time Frame: 6 and 12 months
|
Percentage of participants achieving a clinically meaningful improvement in pain.
Pain improvement measured as a ≥2-point reduction on the 0-10 Numeric Rating Scale (NRS).
NRS is a widely used, validated 0-10, tool for measuring subjective pain intensity, where 0 represents "no pain" and 10 represents "the worst pain imaginable".
|
6 and 12 months
|
|
Change in Pain Disability Index (PDI) score
Time Frame: 6 and 12 months
|
PDI is a 7-item self-report questionnaire used to measure how chronic pain interferes with various aspects of a person's life, with total scores ranging from 0 (no disability) to 70 (maximum disability).
|
6 and 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of pain-related hospital admissions
Time Frame: up to 12 months post cryoneurolysis
|
Number of pain-related hospital admissions in the 12 months before versus the 12 months after cryoneurolysis.
|
up to 12 months post cryoneurolysis
|
|
Number of pain-related emergency department visits
Time Frame: up to 12 months post cryoneurolysis
|
Number of pain-related emergency department visits in the 12 months before versus the 12 months after cryoneurolysis.
|
up to 12 months post cryoneurolysis
|
|
Number of pain-related medication refills
Time Frame: up to 12 months post cryoneurolysis
|
Number of pain-related medication refills in the 12 months before versus the 12 months after cryoneurolysis.
|
up to 12 months post cryoneurolysis
|
|
Number of responders
Time Frame: 6 and 12 month
|
Responders are participants reporting 'much improved' or 'very much improved' using the Patient Global Impression of Change (PGIC).
|
6 and 12 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Charles A Odonkor, MD, Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Bone Diseases
- Musculoskeletal Diseases
- Nervous System Diseases
- Muscular Diseases
- Muscle Hypertonia
- Neuromuscular Manifestations
- Neuromuscular Diseases
- Arthritis
- Joint Diseases
- Rheumatic Diseases
- Spinal Diseases
- Osteoarthritis
- Autonomic Nervous System Diseases
- Neuralgia
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Complex Regional Pain Syndromes
- Muscle Spasticity
- Osteoarthritis, Knee
- Chronic Pain
- Peripheral Nervous System Diseases
- Spondylosis
- Osteoarthritis, Hip
- Causalgia
Other Study ID Numbers
Other Study ID Numbers
- 2000042295
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.